SCHEMBL23033352

SCHEMBL23033352

Cn1nnnc1C(c1ccccc1)N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.52
KMT2A Q03164 6/20 0.48
MEN1 O00255 4/20 0.48
MGLL Q99685 1/20 0.47
CYP3A4 P08684 2/20 0.47
CYP3A5 P20815 2/20 0.47
GLS O94925 1/20 0.46
MAPK1 P28482 1/20 0.46
HRH4 Q9H3N8 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
NR2E1 Q9Y466 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 2/20 0.45
TSHR P16473 1/20 0.45
MCOLN2 Q8IZK6 1/20 0.45
LMNA P02545 1/20 0.44
KDM4E B2RXH2 1/20 0.44
NPC1 O15118 1/20 0.44
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13499546 0.85 ALDH1A1 (0.51) ALDH1A1KMT2AMEN1MGLLCYP3A4
SCHEMBL4013471 0.83 KMT2A (0.67) ALDH1A1KMT2AMEN1MGLLCYP3A4
SCHEMBL23033355 0.80 KMT2A (0.48) ALDH1A1KMT2AMEN1MGLLCYP3A4
SCHEMBL17844495 0.80 KMT2A (0.50) ALDH1A1KMT2AMEN1MGLLCYP3A4
SCHEMBL29761989 0.78 SLC1A2 (0.69) ALDH1A1KMT2ACYP3A4CYP3A5MAPK1
SCHEMBL5688541 0.77 CACNA2D1 (0.60) KMT2AMEN1MGLLCYP3A4CYP3A5
SCHEMBL6797094 0.77 KMT2A (0.58) ALDH1A1KMT2AMEN1MGLLCYP3A4
SCHEMBL20456121 0.77 KMT2A (0.46) ALDH1A1KMT2AMEN1MGLLCYP3A4
SCHEMBL28710689 0.77 KMT2A (0.46) KMT2AMEN1MGLLCYP3A4CYP3A5
SCHEMBL23033354 0.76 KMT2A (0.48) KMT2AMEN1MGLLCYP3A4CYP3A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11040963-B2 Piperazine derivatives for influenza virus inhibitions JANSSEN VACCINES & PREVENTION B.V. (NL) 2021-06-22 US disclosed
WO-2021032209-A1 ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD AND USE THEREOF 四川海思科制药有限公司 2021-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11040963-B2 Piperazine derivatives for influenza virus inhibitions HAVCR2, BAZ2A, MAVS ALDH1A1 631/4885KMT2A 1480/4885MEN1 4153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.